Skip to main content
Español

FDA Alert: WS Global Issues Nationwide Recall of Himalayan Pain Relief Tea Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone

Drug Alerts (FDA)

...conducted with the knowledge of the U.S. Food and Drug Administration. Source: FDA More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter...

FDA Alert: 8th Avenue Pharmacy Issues Voluntary Nationwide Recall of Notoginseng Formula Special Gout Granule Due to the Presence of Hidden Drug Ingredients, Diclofenac and Dexamethasone

Drug Alerts (FDA)

..., NY, 8th Avenue Pharmacy is voluntarily recalling all lots within expiry of Notoginseng Formula Special Gout Granule, distributed by 8th Avenue Pharmacy, to the consumer level. The products have been found to contain undeclared diclofenac and dexamethasone from FDA laboratory analysis. Diclofenac is a...

News: FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma

News & Articles (Drugs.com)

...and 21 percent at 12 months... Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma FRIDAY, Feb. 9, 2024 -- For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd)... More news...

FDA Alert: Latin Foods Market Issues Voluntary Nationwide Recall of Artri King Reforzado Con Ortiga Y Omega 3 Due to the Presence of Undeclared Diclofenac and Dexamethasone

Drug Alerts (FDA)

Reforzado con Ortiga y Omega 3 tablets to the consumer level. FDA analysis has found the product to be tainted with diclofenac and dexamethasone. Diclofenac and dexamethasone are both FDA approved drugs. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) indicated for the management of pain and...

FDA Alert: FDA Alerts Patients and Health Care Professionals About Clinical Trial Results Showing an Increased Risk of Death Associated with Pepaxto (melphalan flufenamide)

Drug Alerts (FDA)

...with each patient in the context of other treatments. Patients currently receiving Pepaxto should also discuss with their health care professional the risks and benefits of receiving Pepaxto. In February 2021, FDA approved Pepaxto under Accelerated Approval for use in combination with dexamethasone to...

News: Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma

News & Articles (Drugs.com)

...... Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months... More news resources FDA Medwatch Drug Alerts Daily...

News: CDC: Tuberculosis Case Counts, Rates Increasing Since 2020

News & Articles (Drugs.com)

...in the Annals of... Dexamethasone No Benefit in HIV-Positive With Tuberculous Meningitis THURSDAY, Oct. 12, 2023 -- For HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone does not confer a benefit with respect to survival, according to a study... More news resources FDA...

FDA Alert: FDA Warns Consumers Not to Purchase or Use Artri and Ortiga Products, Which May Contain Hidden Drug Ingredients

Drug Alerts (FDA)

...dangerous. These products are promoted for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions and are sold on various websites and in some retail stores. FDA laboratory analyses revealed certain Artri and Ortiga products contain the undeclared drug ingredients: Dexamethasone (a...

FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

New Drug Approvals (FDA)

Relapsed or Refractory Multiple Myeloma - February 28, 2022 Carvykti (ciltacabtagene autoleucel) FDA Approval History More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug...

News: Recommendations Issued for Palliative RT for Symptomatic Bone Mets

News & Articles (Drugs.com)

International Journal of Obstetrics... Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are... More news resources FDA...